Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Moderate Buy” by Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $40.60.

DAWN has been the topic of a number of recent analyst reports. Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Finally, Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th.

Day One Biopharmaceuticals Trading Up 5.5 %

Shares of DAWN stock opened at $14.61 on Wednesday. The company has a market capitalization of $1.28 billion, a P/E ratio of -6.14 and a beta of -1.48. The business’s 50 day moving average is $15.24 and its two-hundred day moving average is $13.66. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). On average, research analysts predict that Day One Biopharmaceuticals will post -2.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the sale, the general counsel now owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the transaction, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Adam Dubow sold 3,242 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the transaction, the general counsel now directly owns 16,585 shares in the company, valued at approximately $252,921.25. The disclosure for this sale can be found here. Insiders have sold a total of 45,781 shares of company stock valued at $722,960 in the last 90 days. 8.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DAWN. Bank of New York Mellon Corp raised its holdings in Day One Biopharmaceuticals by 78.3% in the 1st quarter. Bank of New York Mellon Corp now owns 57,490 shares of the company’s stock valued at $570,000 after buying an additional 25,250 shares during the period. MetLife Investment Management LLC purchased a new stake in Day One Biopharmaceuticals in the 1st quarter valued at about $154,000. Rhumbline Advisers purchased a new stake in Day One Biopharmaceuticals in the 1st quarter valued at about $193,000. BlackRock Inc. raised its holdings in Day One Biopharmaceuticals by 54.6% in the 1st quarter. BlackRock Inc. now owns 1,162,916 shares of the company’s stock valued at $11,537,000 after buying an additional 410,797 shares during the period. Finally, American International Group Inc. raised its holdings in Day One Biopharmaceuticals by 92.7% in the 1st quarter. American International Group Inc. now owns 11,294 shares of the company’s stock valued at $112,000 after buying an additional 5,434 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.